Pasithea Therapeutics Corp Stock Profit Margin
| KTTAW Stock | USD 0.02 0.0003 1.50% |
Pasithea Therapeutics Corp fundamentals help investors to digest information that contributes to Pasithea Therapeutics' financial success or failures. It also enables traders to predict the movement of Pasithea Stock. The fundamental analysis module provides a way to measure Pasithea Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pasithea Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | (24.15) | (25.36) |
Pasithea | Profit Margin |
Pasithea Therapeutics Corp Company Profit Margin Analysis
Pasithea Therapeutics' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Pasithea Therapeutics Profit Margin | -25.36 |
Most of Pasithea Therapeutics' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pasithea Therapeutics Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Pasithea Profit Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Pasithea Therapeutics is extremely important. It helps to project a fair market value of Pasithea Stock properly, considering its historical fundamentals such as Profit Margin. Since Pasithea Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pasithea Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pasithea Therapeutics' interrelated accounts and indicators.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Pasithea Pretax Profit Margin
Pretax Profit Margin |
|
Pasithea Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pasithea Therapeutics' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pasithea Therapeutics could also be used in its relative valuation, which is a method of valuing Pasithea Therapeutics by comparing valuation metrics of similar companies.Pasithea Therapeutics is currently under evaluation in profit margin category among its peers.
Pasithea Fundamentals
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.38 | ||||
| Number Of Shares Shorted | 64 | ||||
| Revenue | 486.56 K | ||||
| EBITDA | (15.33 M) | ||||
| Net Income | (15.51 M) | ||||
| Cash And Equivalents | 568.98 K | ||||
| Cash Per Share | 0.07 X | ||||
| Total Debt | 81.68 K | ||||
| Current Ratio | 37.55 X | ||||
| Book Value Per Share | 22.46 X | ||||
| Cash Flow From Operations | (13.43 K) | ||||
| Beta | 0.82 | ||||
| Total Asset | 26.12 M | ||||
| Retained Earnings | (35.32 M) | ||||
| Working Capital | 14.06 M | ||||
| Net Asset | 26.12 M |
About Pasithea Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pasithea Therapeutics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pasithea Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pasithea Therapeutics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pasithea Stock Analysis
When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.